Quiescent cancer cells: Therapeutic targets to overcome immunotherapy resistance?
- PMID: 35690055
- DOI: 10.1016/j.medj.2022.05.013
Quiescent cancer cells: Therapeutic targets to overcome immunotherapy resistance?
Abstract
Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor clinical outcomes. Chemoimmunotherapy improves outcomes in high-risk, early-stage disease, but not all patients benefit. Baldominos and colleagues1 drill down into early TNBC sub-microenvironments using single-cell technologies, characterizing quiescent cancer cell niches that may drive immunotherapy resistance and disease relapse.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests LAE has participated on advisory boards and/or received consulting fees from Genentech, F Hoffman La Roche, Chugai, GPCR, Gilead, Immutep, Immune Onc, Mersana, and Shionogi; she has received royalties from Aduro Biotech. LAE has participated on the steering committee for IMpassion130, KATE2, and KATE3. She is the current Vice President of the Society for the Immunotherapy of Cancer. ACM has received consulting fees from Bristol-Myers Squibb and Roche.
Comment on
-
Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche.Cell. 2022 May 12;185(10):1694-1708.e19. doi: 10.1016/j.cell.2022.03.033. Epub 2022 Apr 20. Cell. 2022. PMID: 35447074 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources